Covariates
obesity, ischemia, stroke, ASCVD, gangrene, abdominal aortic aneurysm, angina pectoris, tall R‐wave, depression, carotid stenosis
OBESITY, ISCHEMIC HEART DISEASE, TRANSIENT ISCHEMIC ATTACK, ISCHEMIA, STROKE, GANGRENE, ISCHEMIC ULCERS, CAROTID STENOSIS, INTERMITTENT CLAUDICATION, TYPE 2 DIABETES, ASCVD, LEFT VENTRICULAR HYPERTROPHY
Multivariable analyses were adjusted for relevant baseline demographic and clinical data, including dichotomized categories of 65 years of age or older, sex, self-identified Black race, self-identified Hispanic ethnicity, educational attainment, prior receipt of antihypertensive drug therapy, aspirin use, estimated glomerular filtration rate, high-density lipoprotein cholesterol level, past or current cigarette use, type 2 diabetes status, history of CHD, history of ASCVD, history of other ASCVD (history of angina pectoris; history of intermittent claudication, gangrene, or ischemic ulcers; history of transient ischemic attack; coronary, peripheral vascular, or carotid stenosis 50% or more documented by angiography or Doppler studies; ischemic heart disease documented by reversible or fixed ischemia on stress thalium or dipyridamole thalium, ST depression ≥1 mm for ≥1 minutes on exercise testing or Holter monitoring; reversible wall motion abnormality on stress echocardiogram; ankle-arm index <0.9; abdominal aortic aneurysm detected by ultrasonography, computed tomography scan, or X-ray; carotid or femoral bruits), history of MI or stroke, history of coronary artery bypass graft, major ST segment depression detected on electrocardiogram, left ventricular hypertrophy (ascertained from centrally coded baseline electrocardiograms using the Minnesota Code criteria of tall R‐wave in the presence of ST‐segment depression or T‐wave inversion), obesity (body mass index [BMI, calculated as weight in kilograms divided by height in meters squared] ≥30), systolic and diastolic blood pressure, and participation in the Lipid Lowering Trial. Because outcome data were evaluated from the time of randomization to the date of the last follow-up, it was not possible to make use of covariate measurements gathered during the in-trial period, extension period, or via external data sources (ie, CMS) after the date of randomization.